Pfizer To Spend 2016 Playing Catch Up In Big Therapeutic Categories
This article was originally published in The Pink Sheet Daily
The big pharma reported the first positive Phase III data for its PCSK9 inhibitor bococizumab and confirmed it is on track to file the SGLT2 inhibitor ertugliflozin in the US this year, but both drugs will compete in markets already crowded with rivals. The same is true for its PD-L1 inhibitor avelumab.
Register for our free email digests: